Table 1 Characteristics of study participants after propensity score matching
Variable | Potential pathogens | p-value | |||
|---|---|---|---|---|---|
No (n = 395,811) | Yes (n = 395,811) | ||||
n | % | n | % | ||
Sex | 0.1749 | ||||
Female | 231,231 | 58.42 | 230,636 | 58.27 | |
Male | 164,580 | 41.58 | 165,175 | 41.73 | |
Age, year | < 0.0001 | ||||
< 40 | 184,612 | 46.64 | 185,276 | 46.81 | |
40–65 | 154,283 | 38.98 | 152,370 | 38.50 | |
65+ | 56,916 | 14.38 | 58,165 | 14.70 | |
Age mean | 44.12 | 16.93 | 44.18 | 17.11 | 0.1710 |
Comorbidities | |||||
Hypothyroidism | 654 | 0.17 | 731 | 0.18 | 0.0384 |
Diabetes mellitus | 39,642 | 10.02 | 39,458 | 9.97 | 0.4905 |
Insomnia | 35,966 | 9.09 | 36,396 | 9.20 | 0.0935 |
Depression | 15,667 | 3.96 | 16,355 | 4.13 | 0.0001 |
Anxiety | 57,312 | 14.48 | 57,795 | 14.60 | 0.1236 |
Dementia | 917 | 0.23 | 1069 | 0.27 | 0.0006 |
Peptic ulcer | 78,871 | 19.93 | 79,257 | 20.02 | 0.2779 |
Obesity | 2627 | 0.66 | 2814 | 0.71 | 0.0110 |
Psoriasis | 2224 | 0.56 | 2535 | 0.64 | 0.0000 |
Burn | 10,722 | 2.71 | 11,280 | 2.85 | 0.0001 |
Gout | 30,102 | 7.61 | 30,276 | 7.65 | 0.4613 |
Dyslipidemia | 45,876 | 11.59 | 46,019 | 11.63 | 0.6158 |
Inflammatory bowel syndrome | 20,993 | 5.30 | 21,043 | 5.32 | 0.8021 |
Hepatitis B | 9671 | 2.44 | 9975 | 2.52 | 0.0281 |
Hepatitis C | 2795 | 0.71 | 3114 | 0.79 | < 0.0001 |
Fibromyalgia | 78,494 | 19.83 | 78,968 | 19.95 | 0.1820 |
Medication | |||||
Doxycycline | 2545 | 0.64 | 2546 | 0.64 | 0.9888 |
Azithromycin | 4807 | 1.21 | 4955 | 1.25 | 0.1317 |
Clarithromycin | 228 | 0.06 | 262 | 0.07 | 0.1244 |
Moxifloxacin | 4219 | 1.07 | 4379 | 1.11 | 0.0827 |
Levofloxacin | 6797 | 1.72 | 6999 | 1.77 | 0.0827 |
Ciprofloxacin | 344 | 0.09 | 364 | 0.09 | 0.4521 |